Year: 2024

Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer

ORION CORPORATION PRESS RELEASE05 JANUARY 2023 at 13:45 EET                      Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684...

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

GRAD1405 uses Gradalis’ breakthrough gene silencing bi-shRNAi technology to specifically reduce the expression of certain mutated KRAS genesExisting therapies have...

error: Content is protected !!